Harbin Jixianglong Biotech Co., Ltd.
Harbin Jixianglong Biotech Co., Ltd. appears in FDA public data with 2 recalls, 0 510(k) clearances, 1 FDA inspection, and 1 compliance action on record. Its most recent recall (D-0380-2026, Class II) was initiated on February 13, 2026.
Summary
- Total Recalls
- 2
- 510(k) Clearances
- 0
- Inspections
- 1
- Compliance Actions
- 1
Recent Recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0380-2026 | Class II | Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106 | February 13, 2026 |
| D-0379-2026 | Class II | Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106- | February 13, 2026 |